GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoSec Medical Inc (FRA:ONMA) » Definitions » Stock Based Compensation

OncoSec Medical (FRA:ONMA) Stock Based Compensation : €1.25 Mil (TTM As of Jan. 2023)


View and export this data going back to 2015. Start your Free Trial

What is OncoSec Medical Stock Based Compensation?

OncoSec Medical's Stock Based Compensation for the three months ended in Jan. 2023 was €0.26 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jan. 2023 was €1.25 Mil.


OncoSec Medical Stock Based Compensation Historical Data

The historical data trend for OncoSec Medical's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoSec Medical Stock Based Compensation Chart

OncoSec Medical Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.06 3.12 3.06 4.35 1.62

OncoSec Medical Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.32 0.30 0.37 0.32 0.26

OncoSec Medical Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jan. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.25 Mil.


OncoSec Medical Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of OncoSec Medical's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoSec Medical (FRA:ONMA) Business Description

Traded in Other Exchanges
Address
24 North Main Street, Pennington, NJ, USA, 08534
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.

OncoSec Medical (FRA:ONMA) Headlines

No Headlines